Clinical evidence for StrataMGT®

A 52-women open-label, single-arm intervention study was conducted in St. Andrews War Memorial Hospital in Brisbane, Australia to evaluate the efficacy and safety of StrataMGT for the management of genital skin conditions.[21]

Patients were diagnosed with Vaginal atrophy (VA), mean age of 66.3 (range 50 - 74 years);
Lichen Sclerosus (LS) and Lichen Simplex Chronicus (LSC), mean age of 54.7 (range 19 - 81 years).

Patients applied StrataMGT daily internally and externally to the genital area for approximately 6 months (short-term analysis, n=52) and up to 2 years (long-term analysis, n=30).

- **Severity of the symptoms:** Patients rated severity of the symptoms using a 10-point scale ranging from 0=normal to 10=worst possible.

The most significant **improvements were seen during the first 6 weeks**, where **symptoms improved up to a 100% resolution** for some patients. **Favorable results** were maintained over **2 years post start of the treatment.**









- **Severity of the condition:** The investigator rated the visual severity of the condition using a 10-point scale ranging from 0=normal to 10=worst possible.

The visual **severity of pathology and clinical signs improved significantly compared to baseline**. The visual pathology of the clitoral hood, urethral area, labia majora and minora, fourchette and perineum showed statistical improvement.



StrataMGT reduces Trans-Epidermal Water Loss (TEWL) by preventing water loss from epidermal and dermal layers, and gas permeability enables **better environment for epidermal migration and healing.**

Treatment **compliance** was very high throughout the study, between 86% and 97% in each visit interval.
No adverse events were observed.

- StrataMGT is a **suitable alternative** treatment for women suffering from various highly symptomatic vulvovaginal conditions.
- StrataMGT is recommended as a **long-term treatment option without the side effects** of topical corticosteroids and vaginally administered hormonal therapy.

Clinical evidence for StrataMGT®

Case series with 19 patients to test the efficacy of StrataMGT on patients presenting for treatment of chronic uncontrolled vulvovaginal conditions, such as Vaginal atrophy (VA) and Lichen Sclerosus (LS).[22]

Dr. Philip Hall, Gynaecologist, MBBS MRMed, FRANZCOG, FRCOG, FACRRM.
Pelvic Medicine Centre, St Andrew's War Memorial Hospital Spring Hill
Brisbane Australia (2018).

THE PELVIC MEDICINE CENTRE
Restoring pelvic function restoring quality of life

Severity of the symptoms: Patients rated severity of the symptoms using a 10-point scale ranging from 0=normal to 10=worst possible.



Patients were followed up over 3 visits (V1-3), averaging 6 week intervals.

Patients mean age of 53.5 (range 30 - 77 years).

StrataMGT provides **hydration whilst protecting the epithelium and mucosa from irritants** such as urine, infection and friction.

The **most significant improvement** was seen for all patients within the first 6 weeks, where **symptoms improved from 33% through to 100% resolution** in some patients.

The clinical control of symptoms was maintained over Visit 2 (3 months) and Visit 3 (4.5 months) in the majority of patients.

A 9-women non-uncontrolled, open-label intervention study was conducted in Orange Coast Women's Medical Group in Laguna Hills, California, USA to evaluate the efficacy and safety of StrataMGT and the improvement of patient's Quality-of-Life (QoL). All patients were postmenopausal, diagnosed with VA, and treated with StrataMGT for 2 months.[23]

Patients rated the impact of vulvar conditions on QoL using Vulvar Quality of Life Index (VQLI) ranging from 0=not impacted, 1-15=mildly impacted, 16-30=moderately impacted, 31-45=severely impacted.



- **The most significant improvement** was seen during the **first month** of treatment - the VQLI score **was reduced by 54%.**
- StrataMGT is **highly efficient** in reducing clinical symptoms associated with VA and improving QoL.